These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9008492)

  • 1. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group.
    Tawil R; McDermott MP; Pandya S; King W; Kissel J; Mendell JR; Griggs RC
    Neurology; 1997 Jan; 48(1):46-9. PubMed ID: 9008492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group.
    Neurology; 1997 Jan; 48(1):38-46. PubMed ID: 9008491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group.
    Kissel JT; McDermott MP; Natarajan R; Mendell JR; Pandya S; King WM; Griggs RC; Tawil R
    Neurology; 1998 May; 50(5):1402-6. PubMed ID: 9595995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone.
    Brooke MH; Fenichel GM; Griggs RC; Mendell JR; Moxley RT; Miller JP; Kaiser KK; Florence JM; Pandya S; Signore L
    Arch Neurol; 1987 Aug; 44(8):812-7. PubMed ID: 3632393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group.
    Tawil R; McDermott MP; Mendell JR; Kissel J; Griggs RC
    Neurology; 1994 Mar; 44(3 Pt 1):442-6. PubMed ID: 8145913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.
    Mendell JR; Moxley RT; Griggs RC; Brooke MH; Fenichel GM; Miller JP; King W; Signore L; Pandya S; Florence J
    N Engl J Med; 1989 Jun; 320(24):1592-7. PubMed ID: 2657428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of handedness on the distribution of muscular weakness of the arm in facioscapulohumeral muscular dystrophy.
    Brouwer OF; Padberg GW; van der Ploeg RJ; Ruys CJ; Brand R
    Brain; 1992 Oct; 115 ( Pt 5)():1587-98. PubMed ID: 1422805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy.
    Fenichel GM; Florence JM; Pestronk A; Mendell JR; Moxley RT; Griggs RC; Brooke MH; Miller JP; Robison J; King W
    Neurology; 1991 Dec; 41(12):1874-7. PubMed ID: 1745340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prednisone on protein metabolism in Duchenne dystrophy.
    Rifai Z; Welle S; Moxley RT; Lorenson M; Griggs RC
    Am J Physiol; 1995 Jan; 268(1 Pt 1):E67-74. PubMed ID: 7840185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.
    Griggs RC; Moxley RT; Mendell JR; Fenichel GM; Brooke MH; Pestronk A; Miller JP
    Arch Neurol; 1991 Apr; 48(4):383-8. PubMed ID: 2012511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit.
    DeSilva S; Drachman DB; Mellits D; Kuncl RW
    Arch Neurol; 1987 Aug; 44(8):818-22. PubMed ID: 3632394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effects of corticosteroid therapy on cardiac and skeletal muscles in muscular dystrophies.
    Hussein G; Mansour L; Ghafar HA; Mostafa FA; Fawaz L
    J Investig Med; 2014 Aug; 62(6):875-9. PubMed ID: 24866459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adapting MRI as a clinical outcome measure for a facioscapulohumeral muscular dystrophy trial of prednisone and tacrolimus: case report.
    Wang LH; Johnstone LM; Bindschadler M; Tapscott SJ; Friedman SD
    BMC Musculoskelet Disord; 2021 Jan; 22(1):56. PubMed ID: 33422031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group.
    Personius KE; Pandya S; King WM; Tawil R; McDermott MP
    Phys Ther; 1994 Mar; 74(3):253-63. PubMed ID: 8115459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beevor's sign and facioscapulohumeral dystrophy.
    Awerbuch GI; Nigro MA; Wishnow R
    Arch Neurol; 1990 Nov; 47(11):1208-9. PubMed ID: 2146943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prednisone in Duchenne muscular dystrophy.
    Drachman DB; Toyka KV; Myer E
    Lancet; 1974 Dec; 2(7894):1409-12. PubMed ID: 4140328
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic trial of beta 2-adrenergic agonist clenbuterol in muscular dystrophies].
    Oya Y; Ogawa M; Kawai M
    Rinsho Shinkeigaku; 2001 Oct; 41(10):698-700. PubMed ID: 11993192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The strength and functional performance in patients with facioscapulohumeral muscular dystrophy.
    Lue YJ; Chen SS
    Kaohsiung J Med Sci; 2000 May; 16(5):248-54. PubMed ID: 10969520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [X-ray computed tomographic scans of lower limb and trunk muscles in facioscapulohumeral muscular dystrophy].
    Horikawa H; Takahashi K; Nishio H; Mano Y; Takayanagi T
    Rinsho Shinkeigaku; 1992 Oct; 32(10):1061-6. PubMed ID: 1297548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.
    LoRusso S; Johnson NE; McDermott MP; Eichinger K; Butterfield RJ; Carraro E; Higgs K; Lewis L; Mul K; Sacconi S; Sansone VA; Shieh P; van Engelen B; Wagner K; Wang L; Statland JM; Tawil R;
    BMC Neurol; 2019 Sep; 19(1):224. PubMed ID: 31506080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.